MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

CytoSorbents Corp

Cerrado

SectorSalud

1.02

Resumen

Variación precio

24h

Actual

Mínimo

1

Máximo

1.04

Métricas clave

By Trading Economics

Ingresos

6.4M

-1.5M

Ventas

-423K

8.7M

Margen de beneficio

-16.94

Empleados

149

EBITDA

8.1M

-468K

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-4.76% downside

Dividendos

By Dow Jones

Próximas Ganancias

12 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

11M

66M

Apertura anterior

1.02

Cierre anterior

1.02

Noticias sobre sentimiento de mercado

By Acuity

17%

83%

25 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

CytoSorbents Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 jul 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 jul 2025, 23:05 UTC

Charlas de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 jul 2025, 20:07 UTC

Ganancias

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 jul 2025, 20:06 UTC

Charlas de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 jul 2025, 19:38 UTC

Charlas de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 jul 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 jul 2025, 19:07 UTC

Charlas de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 jul 2025, 19:03 UTC

Charlas de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 jul 2025, 18:32 UTC

Adquisiciones, fusiones, absorciones

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Adquisiciones, fusiones, absorciones

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 jul 2025, 18:13 UTC

Charlas de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 17:25 UTC

Adquisiciones, fusiones, absorciones

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 jul 2025, 17:24 UTC

Charlas de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 jul 2025, 16:49 UTC

Charlas de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 15:42 UTC

Charlas de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparación entre iguales

Cambio de precio

CytoSorbents Corp Esperado

Precio Objetivo

By TipRanks

-4.76% caída

Estimación a 12 meses

Media 1 USD  -4.76%

Máximo 1 USD

Mínimo 1 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytoSorbents Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.705 / 0.771Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

25 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.